scholarly journals Therapeutic Effects of the Sphingosine 1-Phosphate Receptor Modulator, Fingolimod (FTY720), on Experimental Autoimmune Encephalomyelitis

10.5772/31403 ◽  
2012 ◽  
Author(s):  
Kenji Chiba ◽  
Hirotoshi Kataoka ◽  
Noriyasu Seki ◽  
Kunio Sugahar
Keyword(s):  
Experimental Autoimmune Encephalomyelitis ◽  
Therapeutic Effects ◽  
Autoimmune Encephalomyelitis ◽  
Receptor Modulator ◽  
Sphingosine 1 Phosphate ◽  
Experimental Autoimmune

scholarly journals Partial Deficiency of Sphingosine-1-Phosphate Lyase Confers Protection in Experimental Autoimmune Encephalomyelitis

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e59630 ◽  
Author(s):  
Andreas Billich ◽  
Thomas Baumruker ◽  
Christian Beerli ◽  
Marc Bigaud ◽  
Christian Bruns ◽  
...  
Keyword(s):  
Experimental Autoimmune Encephalomyelitis ◽  
Autoimmune Encephalomyelitis ◽  
Sphingosine 1 Phosphate ◽  
Partial Deficiency ◽  
Experimental Autoimmune

Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis

2017 ◽  
Vol 313 ◽  
pp. 152-160 ◽  
Author(s):  
Weili Liu ◽  
Mei Zhu ◽  
Zhongwang Yu ◽  
Dou Yin ◽  
Fengfeng Lu ◽  
...  
Keyword(s):  
Experimental Autoimmune Encephalomyelitis ◽  
Therapeutic Effects ◽  
Autoimmune Encephalomyelitis ◽  
Experimental Autoimmune

scholarly journals Sphingosine 1-Phosphate Receptor 1 (S1P1) Upregulation and Amelioration of Experimental Autoimmune Encephalomyelitis by an S1P1 Antagonist

2012 ◽  
Vol 83 (2) ◽  
pp. 316-321 ◽  
Author(s):  
Stuart M. Cahalan ◽  
Pedro J. Gonzalez-Cabrera ◽  
Nhan Nguyen ◽  
Miguel Guerrero ◽  
Elizabeth A. George Cisar ◽  
...  
Keyword(s):  
Experimental Autoimmune Encephalomyelitis ◽  
Autoimmune Encephalomyelitis ◽  
Sphingosine 1 Phosphate ◽  
Experimental Autoimmune

Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis

2011 ◽  
Vol 17 (8) ◽  
pp. 939-948 ◽  
Author(s):  
Sarah Al-Izki ◽  
Gareth Pryce ◽  
Samuel J Jackson ◽  
Gavin Giovannoni ◽  
David Baker
Keyword(s):  
Early Intervention ◽  
Experimental Autoimmune Encephalomyelitis ◽  
Immunosuppressive Agents ◽  
Term Treatment ◽  
Autoimmune Encephalomyelitis ◽  
Treatment Benefit ◽  
Secondary Progressive ◽  
Receptor Modulator ◽  
Long Term Treatment ◽  
Experimental Autoimmune

Background: There has been poor translation for the use of immunosuppressive agents from experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), into the treatment of MS. This may be due to the fact that most EAE studies examine prophylactic, pre-treatment regimes that prove to be therapeutically-ineffective in long-established, often progressive, MS. FTY720 (fingolimod/Gilenya) is a sphingosine-1-phosphate receptor modulator. This is a new oral agent that markedly reduces the number of relapses in people with MS, compared with currently licensed injectable agents such as the beta interferons. FTY720 has activity against lymphocytes but may also influence oligodendroglia and could therefore have the potential to influence progressive MS, by promoting remyelination. Methods: The effect of FTY720 was assessed in relapsing-progressive EAE in mice. Results: Early intervention during relapsing EAE could completely inhibit subsequent relapses, inhibited the accumulation of neurodegeneration, and facilitated motor recovery. However, when examined in secondary progressive EAE, that develops after the accumulation of deficit from relapsing disease, long-term treatment with FTY720 failed to slow deterioration when initiated late (4 months) into the disease course. Conclusions: This study indicates that early intervention with immunosuppressive agents may inhibit the generation of the neurodegenerative microenvironment, which is no longer responsive to potent immunosuppression. However, if treatment is initiated too late, progressive, neurological-disease continues unabated. This suggests that immunosuppression is insufficient to control secondary progression in animals, as has been found so far to be the case in MS, and may warrant early intervention with FTY720 for optimal treatment benefit.

scholarly journals Role of Plant-Derived Natural Compounds in Experimental Autoimmune Encephalomyelitis: A Review of the Treatment Potential and Development Strategy

2021 ◽  
Vol 12 ◽  
Author(s):  
Yu-Xin Guo ◽  
Yuan Zhang ◽  
Yu-Han Gao ◽  
Si-Ying Deng ◽  
Li-Mei Wang ◽  
...  
Keyword(s):  
Natural Products ◽  
Experimental Autoimmune Encephalomyelitis ◽  
High Throughput Screening ◽  
Natural Compounds ◽  
Network Pharmacology ◽  
Therapeutic Effects ◽  
Autoimmune Encephalomyelitis ◽  
Novel Technologies ◽  
Natural Medicine ◽  
Experimental Autoimmune

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that is mainly mediated by pathological T-cells. Experimental autoimmune encephalomyelitis (EAE) is a well-known animal model of MS that is used to study the underlying mechanism and offers a theoretical basis for developing a novel therapy for MS. Good therapeutic effects have been observed after the administration of natural compounds and their derivatives as treatments for EAE. However, there has been a severe lag in the research and development of drug mechanisms related to MS. This review examines natural products that have the potential to effectively treat MS. The relevant data were consulted in order to elucidate the regulated mechanisms acting upon EAE by the flavonoids, glycosides, and triterpenoids derived from natural products. In addition, novel technologies such as network pharmacology, molecular docking, and high-throughput screening have been gradually applied in natural product development. The information provided herein can help improve targeting and timeliness for determining the specific mechanisms involved in natural medicine treatment and lay a foundation for further study.

Sign in / Sign up

Export Citation Format

Share Document